By The Life Science Report
Source: Streetwise Reports 07/17/2019
The primary reason for the ratingupcoming trial resultsis discussed in an Echelon Wealth Partners report.
In a July 10 research note, analyst Douglas Loe reported that Echelon Wealth Partners bestowed Top Pick status on Antibe Therapeutics Inc. (ATE:TSX.V; ATBPF:OTCQX) ahead of a seminal Phase 2 data readout expected before the end of Q3/19.
Loe specified that the impending results will come from the company’s 360-patient trial evaluating ATB-346 in multiple doses for osteoarthritis pain. ATB-346 is Antibe’s lead drug candidate, a hydrogen sulfide-releasing naproxen derivative. “We are optimistic that the drug can generate measurable and perhaps clinically meaningful efficacy signals at one or more test doses (150, 200 or 250 milligrams, once daily),” in this study, he added.
Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
One aspect of the data Echelon will be looking at when they’re released is whether or not ATB-346 delivers both meaningful pain relief and gastroenterological protection, and does more so than naproxen treatment alone.
“We believe that pending ATB-346 efficacy data could be platform validating for Antibe’s hydrogen sulfide-based drug modification platform and thus could be relevant to future clinical activities for these two secondary assets, and importantly to our investment thesis and valuation down the road,” Loe highlighted.
Those two secondary assets in the company’s pipeline, Loe noted, are ketoprofen analog ATB-352, possibly targeting chronic severe postsurgical pain, and acetylsalicylic acid analog ATB-340, probably targeting stroke prevention and anticoagulation.
Echelon has a Speculative Buy rating and a CA$1.40 per share target price on Antibe. The stock is currently trading at around CA$0.30 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures from Echelon Wealth Partners, Antibe Therapeutics Inc., July 10, 2019
Echelon Wealth Partners compensates its Research Analysts from a variety of sources. The Research Department is a cost centre and is funded by the business activities of Echelon Wealth Partners including, Institutional Equity Sales and Trading, Retail Sales and Corporate and Investment Banking.
I, Doug Loe, hereby certify that the views expressed in this report accurately reflect my personal views about the subject securities or issuers. I also certify that I have not, am not, and will not receive, directly or indirectly, compensation in exchange for expressing the specific recommendations or views in this report.
Is this an issuer related or industry related publication? Issuer.
Does the Analyst or any member of the Analysts household have a financial interest in the securities of the subject issuer? Yes. If Yes: 1) Is it a long or short position? Long Position; and, 2) What type of security is it? Common Shares & Share Purchase Warrants.
Does the Analyst or household member serve as a Director or Officer or Advisory Board Member of the issuer? No
Does Echelon Wealth Partners Inc. or the Analyst have any actual material conflicts of interest with the issuer? No
Does Echelon Wealth Partners Inc. and/or one or more entities affiliated with Echelon Wealth Partners Inc. beneficially own common shares (or any other class of common equity securities) of this issuer which constitutes more than 1% of the presently issued and outstanding shares of the issuer? Yes
During the last 12 months, has Echelon Wealth Partners Inc. provided financial advice to and/or, either on its own or as a syndicate member, participated in a public offering, or private placement of securities of this issuer? Yes
During the last 12 months, has Echelon Wealth Partners Inc. received compensation for having provided investment banking or related services to this Issuer? Yes
Has the Analyst had an onsite visit with the Issuer within the last 12 months? No
Has the Analyst or any Partner, Director or Officer been compensated for travel expenses incurred as a result of an onsite visit with the Issuer within the last 12 months? No
Has the Analyst received any compensation from the subject company in the past 12 months? No
Is Echelon Wealth Partners Inc. a market maker in the issuers securities at the date of this report? No
( Companies Mentioned: ATE:TSX.V; ATBPF:OTCQX,